Possible Benefit of Angiotensin II Receptor Blockers in COVID-19 Patients: A Case Series

Table 1

Clinical characteristics and treatments of patients.

	Patient
	Case 1	Case 2	Case 3	Case 4
Sex	Male	Male	Male	Male
Age (y)	28	71	49	78
Weight (kg)	85	75	83	69
Incubation period	Unknown	Unknown	9	Unknown
Interval between symptomonset and admission (days)	12	11	15	12
Initial symptoms	Fever, myalgia	Fever, myalgia, cough, sputum	Fever, myalgia	Fever, myalgia, cough, sputum
Symptoms at admission	Fever, dyspnea, myalgia, cough, sputum	Fever, dyspnea, myalgia, cough, sputum	Fever, dyspnea, myalgia, cough, sputum	Fever, dyspnea, myalgia, cough, sputum, chest discomfort, diarrhea, headache
Smoking	None	Ex-smoker	None	None
Underlying disease
Diabetes	None	Yes	None	Yes
Hypertension	None	Yes	Yes	Yes
Ischemic heart disease	None	None	None	Yes
Chest X-ray	Focal consolidation in both lower lobes	Diffuse patchy consolidation	Diffuse patchy consolidation	Diffuse patchy consolidation
Oxygen demand (L)	3	3	5	3
Treatment
Antiviral agent
Lopinavir/ritonavir	Yes	Yes	Yes	Yes
Hydroxychloroquine	Yes	Yes	Yes	Yes
Antibiotics
Piperacillin/tazobactam	No	Yes	Yes	Yes
Levofloxacin	No	Yes	Yes	Yes
Azithromycin	Yes	No	No	No